We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+16.4%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$6.8B
AUM Growth
+$1.2B
Cap. Flow
+$636M
Cap. Flow %
9.34%
Top 10 Hldgs %
38.38%
Holding
154
New
24
Increased
52
Reduced
26
Closed
34

Top Buys

Rank Stock Value
1
RLYP
RELYPSA INC COM
RLYP
+$204M
2
PRGO icon
Perrigo
PRGO
+$111M
3
ABBV icon
AbbVie
ABBV
+$99.2M
4
CELG
Celgene Corp
CELG
+$71.2M
5
ZBH icon
Zimmer Biomet
ZBH
+$70.4M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$169M
2
ELV icon
Elevance Health
ELV
+$69M
3
WCRX
WARNER CHILCOTT PLC ORD SHS CL A (IRL)
WCRX
+$56.2M
4
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$53.1M
5
CBST
CUBIST PHARMACEUTICALS INC
CBST
+$52.7M

Sector Composition

Rank Sector Weight
1 Healthcare 85.54%
2 Miscellaneous 13.17%
3 Financials 1.18%
4 Technology 0.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IQV icon
126
IQVIA
IQV
$43.1B
– –
-440,000
Closed -$19.7M
MOH icon
127
CALL
Molina Healthcare
MOH
$11.2B
– –
-215,300
Closed -$7.67M
MYGN icon
128
PUT
Myriad Genetics
MYGN
$363M
– –
-30,000
Closed -$705K
SPY icon
129
State Street SPDR S&P 500 ETF Trust
SPY
$803B
– –
-300,000
Closed -$53.1M
VNDA icon
130
PUT
Vanda Pharmaceuticals
VNDA
$311M
– –
-139,400
Closed -$1.53M
INFI
131
CALL
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
– –
-150,000
Closed -$2.62M
ENDP
132
DELISTED
Endo International plc
ENDP
– –
-105,000
Closed -$4.77M
ALXN
133
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-100,000
Closed -$11.6M
AGN
134
CALL
DELISTED
Allergan plc
AGN
– –
-150,000
Closed -$21.6M
WCG
135
DELISTED
Wellcare Health Plans, Inc.
WCG
– –
-272,000
Closed -$19M
KERX
136
CALL
DELISTED
Keryx Biopharmaceuticals Inc
KERX
– –
-250,000
Closed -$2.52M
AEGR
137
PUT
DELISTED
Aegerion Pharmaceuticals
AEGR
– –
-50,000
Closed -$4.29M
HNT
138
CALL
DELISTED
HEALTH NET INC
HNT
– –
-250,000
Closed -$7.92M
WX
139
DELISTED
WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS
WX
– –
-31,500
Closed -$863K
RCPT
140
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
– –
-644,450
Closed -$16.7M
AVNR
141
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
– –
-1,863,400
Closed -$7.88M
DNDN
142
DELISTED
DENDREON CORPORATION
DNDN
– –
-868,000
Closed -$2.54M
VPHM
143
CALL
DELISTED
VIROPHARMA INC
VPHM
– –
-250,000
Closed -$9.81M
VPHM
144
PUT
DELISTED
VIROPHARMA INC
VPHM
– –
-100,000
Closed -$3.93M
ONXX
145
PUT
DELISTED
ONYX PHARMACEUTICALS INC
ONXX
– –
-112,300
Closed -$14M
WCRX
146
DELISTED
WARNER CHILCOTT PLC ORD SHS CL A (IRL)
WCRX
– –
-2,449,100
Closed -$56.2M
CELGZ
147
DELISTED
Celgene Corporation Contingent Value Rights
CELGZ
– –
-360,900
Closed -$2.9M
BCR
148
DELISTED
CR Bard Inc.
BCR
– –
-38,000
Closed -$4.38M
MDVN
149
PUT
DELISTED
MEDIVATION, INC.
MDVN
– –
-100,000
Closed -$3M
2 3 4 5
6

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q4 2013 Portfolio in Review

As of Q4 2013, OrbiMed held 154 positions worth $6.8B, up 21% from $5.6B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

OrbiMed deployed $636M of net new capital in Q4 2013, opening 24 new positions and adding to 52 existing holdings. Its largest new stake was RELYPSA INC COM: 9,941,549 shares worth $249M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 85% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Merck, an estimated $169M trimmed.

  • OrbiMed's largest Q4 2013 buy was RELYPSA INC COM: 9,941,549 shares worth $249M.
  • OrbiMed added most to AbbVie in Q4 2013, an estimated $99.2M increase.
  • OrbiMed's biggest Q4 2013 reduction was Merck, cutting an estimated $169M.
  • OrbiMed fully exited WARNER CHILCOTT PLC ORD SHS CL A (IRL) in Q4 2013, selling an estimated $56.2M.
  • OrbiMed's ten largest holdings make up 38% of its $6.8B portfolio in Q4 2013.
  • OrbiMed opened 24 new positions and closed 34 in Q4 2013.
  • OrbiMed's portfolio value rose 21% quarter-over-quarter to $6.8B.

Based on OrbiMed's 13F filing for Q4 2013, filed 14 Feb 2014.